Associated Papers
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
38496837 (PubMed )
Supplement: mmc1.xlsx › Sheet1
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
35304574 (PubMed )
Supplement: 41388_2022_2263_MOESM5_ESM.xlsx › Supplementary_Table_4
Endoplasmic reticulum chaperone GRP78/BiP is critical for mutant Kras-driven lung tumorigenesis.
Rangel DF et al.
Oncogene, 2021
Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer.
Kaserer T et al.
Cell Chemical Biology, 2018
EGFR G796D mutation mediates resistance to osimertinib.
Zheng D et al.
Oncotarget, 2017
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Russo M et al.
Cancer Discovery, 2016
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
21531810 (PubMed )
Supplement: 10780432ccr103408-sup-ccr_10-3408_wu_t4.pdf
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
21575214 (PubMed )
Supplement: 1476-4598-10-54-S3.XLS › mutations.txt
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
Onitsuka T et al.
Lung Cancer (amsterdam, Netherlands), 2010
Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
Boldrini L et al.
Oncology Reports, 2009
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations.
Sugio K et al.
Lung Cancer (amsterdam, Netherlands), 2009
A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: the role of a novel G796A mutation in exon 20 of EGFR.
Uramoto H et al.
Anticancer Research, 0
Select a paper to view details